Gyre Therapeutics (GYRE) Accounts Payables (2016 - 2026)
Gyre Therapeutics has reported Accounts Payables over the past 16 years, most recently at $124000.0 for Q4 2025.
- Quarterly Accounts Payables rose 14.81% to $124000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124000.0 through Dec 2025, up 14.81% year-over-year, with the annual reading at $124000.0 for FY2025, 14.81% up from the prior year.
- Accounts Payables was $124000.0 for Q4 2025 at Gyre Therapeutics, down from $556000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $6.4 million in Q4 2021 and troughed at $5000.0 in Q2 2023.
- The 5-year median for Accounts Payables is $287000.0 (2024), against an average of $1.2 million.
- Year-over-year, Accounts Payables plummeted 99.66% in 2023 and then surged 5320.0% in 2024.
- A 5-year view of Accounts Payables shows it stood at $6.4 million in 2021, then crashed by 98.1% to $122000.0 in 2022, then surged by 190.98% to $355000.0 in 2023, then tumbled by 69.58% to $108000.0 in 2024, then grew by 14.81% to $124000.0 in 2025.
- Per Business Quant, the three most recent readings for GYRE's Accounts Payables are $124000.0 (Q4 2025), $556000.0 (Q3 2025), and $71000.0 (Q2 2025).